---
title: "Rafael Holdings merges with Cyclo Therapeutics; Phase 3 trial for Niemann-Pick disease fully enrolled, results due mid-2025."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233271871.md"
description: "The Phase 3 clinical trial for Trappsol® Cyclo™ by Cyclo Therapeutics targeting Niemann-Pick Disease Type C1, a rare and fatal genetic disorder, has reached full enrollment. The 48-week interim analysis is anticipated to unveil results around mid-2025. This trial specifically aims to assess the effectiveness of TransportNPC™ in treating this illness. Niemann-Pick Disease Type C1 is a severe condition, and the study's outcome could potentially bring hope to individuals affected by it."
datetime: "2025-03-26T11:07:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233271871.md)
  - [en](https://longbridge.com/en/news/233271871.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233271871.md)
generator: "portal-rs"
---

# Rafael Holdings merges with Cyclo Therapeutics; Phase 3 trial for Niemann-Pick disease fully enrolled, results due mid-2025.

The Phase 3 clinical trial for Trappsol® Cyclo™ by Cyclo Therapeutics targeting Niemann-Pick Disease Type C1, a rare and fatal genetic disorder, has reached full enrollment. The 48-week interim analysis is anticipated to unveil results around mid-2025. This trial specifically aims to assess the effectiveness of TransportNPC™ in treating this illness. Niemann-Pick Disease Type C1 is a severe condition, and the study's outcome could potentially bring hope to individuals affected by it.

### Related Stocks

- [CYTH.US](https://longbridge.com/en/quote/CYTH.US.md)

## Related News & Research

- [Quoin says FDA grants rare pediatric disease designation for QRX003 in peeling skin syndrome](https://longbridge.com/en/news/298320213.md)
- [Kiora Pharmaceuticals Bolsters Leadership in Clinical Development](https://longbridge.com/en/news/298310859.md)
- [Vor Bio highlights telitacicept BAFF/APRIL inhibitor as lead program in B cell-driven autoimmune diseases](https://longbridge.com/en/news/298307942.md)
- [10:31 ETSarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight](https://longbridge.com/en/news/298336160.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**